An observational, retrospective study comparing risk of hypoglycemia with Toujeo with other basal insulins in type 2 diabetes patients

Trial Profile

An observational, retrospective study comparing risk of hypoglycemia with Toujeo with other basal insulins in type 2 diabetes patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin degludec; Insulin detemir
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DELIVER 2
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Apr 2017 New trial record
    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
    • 02 Apr 2017 Results presented at the Endocrine Society 2017 Annual Meeting (ENDO 2017), according to a Sanofi media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top